SYT12 and Parkinson disease: Meanwhile, L-dopa (L-3,4-dihydroxyphenylalanine), which has been approved for Parkinson’s disease, could reduce cellular SYT12 expression, allowing cells to acquire a cellular phenotype similar to SYT12 knockdown.